{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:41:50Z","timestamp":1793724110199,"version":"4.6.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001412","name":"CSIR","doi-asserted-by":"publisher","award":["HCP-0040"],"award-info":[{"award-number":["HCP-0040"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001410","name":"Human Resource Development Group","doi-asserted-by":"publisher","award":["381-1439-5723\/2K24\/1"],"award-info":[{"award-number":["381-1439-5723\/2K24\/1"]}],"id":[{"id":"10.13039\/501100001410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001410","name":"Human Resource Development Group","doi-asserted-by":"publisher","award":["\/2026\/026"],"award-info":[{"award-number":["\/2026\/026"]}],"id":[{"id":"10.13039\/501100001410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001332","name":"Council for Scientific and Industrial Research, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bmcl.2026.130687","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:19:04Z","timestamp":1779203944000},"page":"130687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["New thiazole-biaryls as small molecule immunomodulators (SMIs) targeting PD-1\/PD-L1 axis"],"prefix":"10.1016","volume":"138","author":[{"given":"Swapnanjali","family":"Karamtoth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maresha","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil Anil","family":"Sule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baji Baba","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya Jyothi","family":"Alli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Ummanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surender Singh","family":"Jadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130687_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.bmcl.2026.130687_bb0010","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0960-9822(95)00175-8","article-title":"T-Cell Activation: Two for T","volume":"5","author":"Guerder","year":"1995","journal-title":"Curr Biol"},{"key":"10.1016\/j.bmcl.2026.130687_bb0015","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.bmcl.2026.130687_bb0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1034\/j.1600-0625.2000.009005313.x","article-title":"Dendritic cell activation by danger and antigen-specific T-cell signalling","volume":"9","author":"AD","year":"2000","journal-title":"Exp Dermatology Rev Artic"},{"key":"10.1016\/j.bmcl.2026.130687_bb0025","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bmcl.2026.130687_bb0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0167-5699(90)90085-N","article-title":"Role of the CD28 receptor in T-cell activation","volume":"11","author":"June","year":"1990","journal-title":"Immunol Today"},{"key":"10.1016\/j.bmcl.2026.130687_bb0035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nm0804-801","article-title":"Regulatory T cells and mechanisms of immune system control","volume":"10","author":"O\u2019garra","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2026.130687_bb0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmcl.2026.130687_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.bmcl.2026.130687_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2026.130687_bb0055","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2026.130687_bb0060","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2026.130687_bb0065","series-title":"CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation","first-page":"99","author":"Chikuma","year":"2017"},{"key":"10.1016\/j.bmcl.2026.130687_bb0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmcl.2026.130687_bb0075","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2026.130687_bb0080","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5858\/arpa.2016-0361-RA","article-title":"Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)\/PD-L1 blockade: a key player against various cancers","volume":"141","author":"Guan","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.bmcl.2026.130687_bb0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmcl.2026.130687_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030335","article-title":"Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4","volume":"15","author":"Pandey","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmcl.2026.130687_bb0095","article-title":"Immune checkpoint molecules: a review on pathways and immunotherapy implications","volume":"13","author":"Rezazadeh-Gavgani","year":"2025","journal-title":"Immunity Inflamm Dis"},{"key":"10.1016\/j.bmcl.2026.130687_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105123","article-title":"PD-1\/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects","volume":"22","author":"Munari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2026.130687_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmcl.2026.130687_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050880","article-title":"Revolutionary cancer therapy for personalization and improved efficacy: strategies to overcome resistance to immune checkpoint inhibitor therapy","volume":"17","author":"Almawash","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130687_bb0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.36922\/ITPS025140018","article-title":"Precision medicine and beyond: evolving roles of targeted therapy, immunotherapy, and artificial intelligence in oncology","volume":"8","author":"Li","year":"2025","journal-title":"INNOSC Theranostics Pharmacol Sci"},{"key":"10.1016\/j.bmcl.2026.130687_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2026.130687_bb0125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2026.130687_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383456","article-title":"Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges","volume":"15","author":"Javed","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2026.130687_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmcl.2026.130687_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14010068","article-title":"Inhibitors of immune checkpoints: small molecule-and peptide-based approaches","volume":"14","author":"Fuchs","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.bmcl.2026.130687_bb0145","article-title":"Design, synthesis, and biological evaluation of chroman derivatives as PD-1\/PD-L1 antagonists","volume":"64","author":"Wang","year":"2024","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmcl.2026.130687_bb0150","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD- L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.bmcl.2026.130687_bb0155","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1039\/D3MD00655G","article-title":"Progress in small-molecule inhibitors targeting PD-L1","volume":"15","author":"Xu","year":"2024","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmcl.2026.130687_bb0160","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1021\/acs.jmedchem.7b00293","article-title":"Small-molecule inhibitors of the Programmed Cell Death-1\/Programmed Death-Ligand 1 (PD-1\/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1","volume":"60","author":"Guzik","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130687_bb0165","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2026.130687_bb0170","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1016\/j.apsb.2022.04.007","article-title":"Novel phthalimides regulating PD-1\/PD-L1 interaction as potential immunotherapy agents","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2026.130687_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107376","article-title":"Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1\/PD-L1 interaction","volume":"147","author":"Xu","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130687_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115468","article-title":"Design, synthesis, and evaluation of PD-1\/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold","volume":"256","author":"Cai","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130687_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24152804","article-title":"CA-170 - a potent small-molecule PD-L1 inhibitor or not?","volume":"24","author":"Musielak","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130687_bb0190","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1529\/biophysj.108.134973","article-title":"A quantitative model of thermal stabilization and destabilization of proteins by ligands","volume":"95","author":"Cimmperman","year":"2008","journal-title":"Biophys J"},{"key":"10.1016\/j.bmcl.2026.130687_bb0195","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1021\/acschembio.2c00583","article-title":"Exploring the surface of the ectodomain of the PD-L1 immune checkpoint with small-molecule fragments","volume":"17","author":"Kitel","year":"2022","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2026.130687_bb0200","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/nprot.2007.321","article-title":"The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability","volume":"2","author":"Niesen","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bmcl.2026.130687_bb0205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2600154X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2600154X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:35:38Z","timestamp":1783172138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2600154X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"alternative-id":["S0960894X2600154X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130687","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New thiazole-biaryls as small molecule immunomodulators (SMIs) targeting PD-1\/PD-L1 axis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130687"}}